8-K: Revvity Reports Q2 2026 Results, Divests China IDX Business

Revvity, Inc. announced its second quarter 2026 financial results, reporting revenue of $730 million and adjusted EPS of $1.41, while also entering an agreement to divest its China Immunodiagnostics business for up to $200 million.

Summary

• Revvity, Inc. reported financial results for the second quarter ended July 5, 2026.
• Revenue for the quarter was $730 million, an increase from $720 million in the same period last year.
• GAAP EPS from continuing operations was $0.48, compared to $0.47 year-over-year.
• Adjusted EPS from continuing operations was $1.41, an increase from $1.18 in the prior year.
• The company entered into a definitive agreement to divest its Immunodiagnostics business in China (China IDX) for up to $200 million, expected to close by the end of 2027.
• Pro forma revenue was $711 million, with pro forma adjusted EPS of $1.41.
• Full year 2026 guidance on a pro forma basis projects total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted EPS of $5.30-$5.40.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by improved operational performance and strategic divestiture, though tempered by the complexities of the divestiture and ongoing market dynamics.

Positives

• Revenue increased to $730 million from $720 million in the prior year's second quarter.
• Adjusted EPS from continuing operations grew to $1.41 from $1.18 year-over-year.
• Pro forma adjusted operating profit margin improved to 29.3% from 26.5% in the prior year's second quarter.
• Diagnostics segment revenue increased by 12% year-over-year on a pro forma basis.
• Full year 2026 pro forma revenue guidance is projected at $2.83-$2.86 billion.
• Full year 2026 pro forma organic revenue growth is forecasted at 4-5%.
• Full year 2026 pro forma adjusted EPS guidance is set at $5.30-$5.40.

Negatives

• Life Sciences segment revenue decreased by 2% year-over-year on a pro forma basis.
• Life Sciences segment adjusted operating profit margin slightly decreased to 31.1% from 31.6% year-over-year.
• The divestiture of the China IDX business, which represented approximately 6% of fiscal year 2025 revenue, introduces complexity and uncertainty regarding the closing timeline.
• GAAP operating profit margin from continuing operations decreased to 12.2% from 12.6% year-over-year.

Risks

• Markets into which the company sells its products may decline or not grow as anticipated.
• Fluctuations in the global economic and political environments, including tariff increases.
• Failure to introduce new products in a timely manner.
• Inability to execute acquisitions and divestitures or successfully integrate acquired businesses.
• Intense competition in the industry.
• Disruptions in third-party package delivery and import/export services.
• Uncertainties related to the development and use of AI in product offerings and internal operations.
• Potential for product liability claims.

Future Outlook

For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.

Management Comments

• "Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base," said Prahlad Singh, president and chief executive officer of Revvity.
• "As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth."

Industry Context

StockSavvy.ai notes that Revvity's performance in the Diagnostics segment shows robust growth, aligning with broader trends of increased demand for diagnostic solutions. However, the slight decline in the Life Sciences segment may reflect sector-specific headwinds or a temporary slowdown in certain research areas.

Stakeholder Impact

• Shareholders: Potential for increased value through strategic divestiture and reinvestment in growth areas, alongside improved operational performance reflected in adjusted EPS.
• Employees: Potential impact from the divestiture of the China IDX business, and potential for increased investment in business growth.
• Customers: Continued provision of health science solutions, with potential for enhanced offerings due to reinvestment.
• Suppliers: Continued business operations, with potential shifts in supply chain dynamics related to the China IDX divestiture.

Next Steps

• Complete the divestiture of the China Immunodiagnostics business by the end of 2027.
• Invest in business growth opportunities using a portion of tariff refunds.
• Continue to monitor and adapt to market dynamics in Life Sciences and Diagnostics segments.
• Execute on full-year 2026 financial guidance.

Key Dates

Recommendation

The company is showing improved operational performance with strong adjusted EPS growth and a positive outlook for the full year. However, the divestiture of a significant business unit introduces complexity and a long closing timeline, while the Life Sciences segment shows a slight decline. These factors warrant a 'hold' recommendation pending clearer visibility on the divestiture's completion and sustained growth across all segments.

Keywords

Revvity, Financial Results, Q2 2026, Divestiture, China Immunodiagnostics, Pro Forma, Adjusted EPS, Revenue Growth